iBrain diagnoses sleep disorders; MIT recognition

Donna Cusano

NeuroVigil, an early-stage company last mentioned here as part of the mHealth Summit 2009 report on wireless sensors [TA 4 Nov], may still be in test of their single-electrode sensor for testing brain activity–and the algorithms needed to make sense out of that signal–but their founder, Philip Low, has just been named as one of the top young (under 35) innovators of 2010 by the MIT Technology Review magazine. Right now the testing is on sleep monitoring, but last October drugmaker Roche contracted to use iBrain for clinical trials, and additional potential areas include diagnosis of neurological conditions such as dementia, traumatic brain injury and schizophrenia. iHealthBeat (short article), San Diego Union-Tribune. NeuroVigil website.